ArticleCancer chemotherapy and pharmacology2021

The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.

Song Mu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.